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0022-2836/© 2009 Elsevier Ltd. Open accThe common Z mutant (Glu342Lys) of α1-antitrypsin results in the forma-
tion of polymers that are retained within hepatocytes. This causes liver
disease whilst the plasma deficiency of an important proteinase inhibitor
predisposes to emphysema. The Thr114Phe and Gly117Phe mutations
border a surface cavity identified as a target for rational drug design. These
mutations preserve inhibitory activity but reduce the polymerisation of
wild-type native α1-antitrypsin in vitro and increase secretion in a Xenopus
oocyte model of disease. To understand these effects, we have crystallised
both mutants and solved their structures. The 2.2 Å structure of Thr114Phe
α1-antitrypsin demonstrates that the effects of the mutation are mediated
entirely by well-defined partial cavity blockade and allows in silico
screening of fragments capable of mimicking the effects of the mutation.
The Gly117Phe mutation operates differently, repacking aromatic side
chains in the helix F–β-sheet A interface to induce a half-turn downward
shift of the adjacent F helix. We have further characterised the effects of
these two mutations in combination with the Z mutation in a eukaryotic cell
model of disease. Both mutations increase the secretion of Z α1-antitrypsin
in the native conformation, but the double mutants remain more
polymerogenic than the wild-type (M) protein. Taken together, these data
support different mechanisms by which the Thr114Phe and Gly117Phe
mutations stabilise the native fold of α1-antitrypsin and increase secretion of
monomeric protein in cell models of disease.© 2009 Elsevier Ltd. Open access under CC BY license.Keywords: serpin; α1-antitrypsin; polymerisation; rational drug design;
conformational diseaseEdited by M. GussIntroduction
The plasma protein α1-antitrypsin is principally
synthesised by hepatocytes and protects lung tissue
from degradation by inhibiting neutrophil elas-
tase.1 It is the archetypal member of the serpiness:
r authors.
rotease inhibitor; PDB,
graphic symmetry;
polyethylene glycol.
ess under CC BY license.(serine protease inhibitor) superfamily of proteins.2
In common with other inhibitory serpins, the
native fold of α1-antitrypsin is metastable and
this property is utilised in the characteristic serpin
mechanism of action.3 The reactive loop of the
molecule is oriented into solution as an ideal sub-
strate for its target protease. Following docking,
elastase cleaves the P1–P1′4 bond of α1-antitrypsin,
allowing the P1–P14 residues of the reactive loop to
insert as an additional strand within β-sheet A. The
enzyme remains bound to the P1 residue in a
catalytic intermediate state and is translocated 70 Å
from one pole of the molecule to the other.5 The
energy released by the formation of the new β-
strand disables the catalytic site and stabilises the
858 Crystal Structures of Thr114Phe and Gly117Phe α1-Antitrypsincovalently bound complex, which is then rapidly
cleared from the circulation.6
This dynamic mechanism renders α1-antitrypsin
vulnerable to point mutations, predisposing it to
alternative, pathogenic, conformational transitions—Fig. 1 (legend oin particular self-association into polymer chains.7
These accumulate within the endoplasmic reticulum
of hepatocytes rather than enter the circulation. The
most clinically significant of these is the Z mutation
(Glu342Lys) carried by 1 in 27 of North Europeann next page)
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ciency of circulatingα1-antitrypsinwith levels that are
10–15% of those found in homozygotes for M (wild
type) α1-antitrypsin. Disease ensues from both the
toxic effects of polymers aggregated within hepa-
tocytes (neonatal hepatitis, cirrhosis and hepatocel-
lular carcinoma) and the loss of antiprotease activity
within the lung (emphysema).
Over the last 15 years, biochemical, biophysical
and structural studies have defined the general
scheme of α1-antitrypsin polymerisation.7–11 This
proceeds via an initial monomeric intermediate
termed M⁎ in a conformation that is activated for
the formation of polymers. The existence of this
initiating species is indicated by fluorescence studies
of α1-antitrypsin polymerisation kinetics and by the
structure of the thermodynamically stabilised yet
highly polymerogenic δ conformer of the closely
related protein, α1-antichymotrypsin.
8–12 These stu-
dies support the hypothesis that the native-to-M⁎
transition results from dysregulated opening of β-
sheet A and allows the reactive site loop of a
neighbouring molecule to insert aberrantly as an
extra β-strand. Successive intermolecular loop–sheet
interactions lengthen the polymer chain. Recently,
an alternative model has been proposed, based upon
the structure of a self-terminating dimer of the
serpin antithrombin,13 emphasising polymerisationFig. 1. Structure of Thr114Phe α1-antitrypsin and in silico
antitrypsin shown in cyan with key structural features colour
blue, the shutter region in orange, helix D in green, helix F in b
flanking β-sheet A is indicated (ellipse). (b) Superposition of w
α1-antitrypsin with plot of the r.m.s.d. between the main chain
native fold in the presence of the Thr114Phe mutation. TUG-
panel) α1-antitrypsin indicates that the mutation confers i
concentration. CD spectroscopy allows urea stability to be com
with varying urea concentrations are shown for wild-type and
allow direct comparison of the loss of initial signal. Curves w
equation modelling a simple two-state denaturation as des
commenced at 0.7M urea for the wild-type protein (black curve
(blue curve, filled circles). The transition midpoints (assuming
points (3.4 M urea for wild-type α1-antitrypsin and 3.5 M fo
density for the Thr114Phe mutation site (boxed) prior to restra
type α1-antitrypsin (1QLP with the mutation site modelled as a
electron density map shown in dark blue (contoured at 1 σ). Po
Fo−Fc difference map shown in red (contoured at 3 σ). The sa
The surface-accessible cavity flanking β-sheet A, shown in clo
structure of Thr114Phe (middle panel, cyan) α1-antitrypsin
occupied by the Thr114Phe mutation within the cavity def
compounds to mimic its effects [right panel, cyan mesh, with
representation)]. (f) Results of proof-of-principle fragment scre
successfully docked using the induced fit protocol. Right pane
shown correspond to 903 poses). All are highly drug-like and
517 and the Rule of 3.18 Heat map colouring indicates ligand–ta
≤2.5 Å, red). Glide docking score values b−6.8 kcal/mol corre
−8.2 kcal/mol are consistent with predicted submicromolar
indicates increased likelihood of a docked moiety mimicking
more extensive structural optimisation during drug design.1
particularly scoring using both Glide SP and Prime scoring alg
favourable characteristics following induced fit docking. The p
surface, and ‘receptor residues’ (Asn104, Thr114 and His139)
correspond to those of receptor site residues optimised for th
(oxygen, red; nitrogen, dark blue; fluorine, light blue; sulfur, o
docking score. Middle panel: the five ligands top-ranked by pro
the ‘favourable outlier group’ defined in (f).as an alternative endpoint on the folding pathway.
The repeating subunit of the proposed polymer is
considerably unfolded compared to the native struc-
ture with intermolecular linkage occurring via a β-
hairpin formed from the reactive loop and a con-
tiguous β-strand.
Both proposed mechanisms of polymerisation
share key characteristics that can be exploited for
the purposes of rational drug design. In both cases,
increasing stability of the native fold will reduce the
population of the unstable intermediate. Moreover,
in both cases, polymerisation requires expansion of
β-sheet A and the formation of a six-stranded sheet.
For α1-antitrypsin, this involves the sealing of a
solvent-accessible cavity flanking β-sheet A.14 This,
therefore, represents an attractive target for rational
drug design as small molecules binding here will
impede expansion of β-sheet A and, thus, prevent
polymerisation by an allosteric mechanism. Evi-
dence for this comes from the effects of mutating
either of two residues bordering the cavity—Thr114
and Gly117—to phenylalanine. Both mutations
reduce polymerisation of α1-antitrypsin by an
order of magnitude in vitrowhilst leaving inhibitory
activity unaffected.14 Moreover, both mutations
partially rescue the defect in the total levels of
secreted Z α1-antitrypsin in a eukaryotic cell model
of disease. The importance of this cavity isfragment screen. (a) Crystal structure of Thr114Phe α1-
ed. The reactive loop is depicted in red, β-sheet A in dark
ronze and strand 1 of β-sheet C (s1C) in purple. The cavity
ild-type (PDB code: 1QLP,16 yellow) and Thr114Phe (cyan)
s (red) and side chains (blue). (c) Increased stability of the
PAGE of wild-type (upper panel) and Thr114Phe (middle
ncreased stability of the native fold to increasing urea
pared more directly. Ellipticity values measured at 222 nm
Thr114Phe α1-antitrypsin (n=3). Values are normalised to
ere fitted in Grafit 3.0 (Erithacus Software Ltd.) using an
cribed previously.8 Unfolding measured by this method
, open circles) and 1.2M urea for Thr114Phe α1-antitrypsin
complete unfolding at 8 M urea) were reached at similar
r Thr114Phe α1-antitrypsin) in both profiles. (d) Electron
ined refinement (upper panel). The 2.0-Å structure of wild-
n alanine was used as the search model, giving the 2Fo−Fc
sitive density for the phenylalanine residue appears in the
me site is shown in the refined structure (lower panel). (e)
se up for wild-type (left panel, yellow) and in the refined
with side chains and electrostatic surfaces. The volume
ines a pharmacophore target for screening of fragment
in the wild-type α1-antitrypsin cavity (transparent surface
en. Left panel: Ensemble of the 65 highest-scoring ligands
l: 4-D plot showing characteristics of these ligands (results
favourable for drug development according to the Rule of
rget centroid proximity (≥5.0 Å, yellow; 2.5–5.0 Å, orange;
spond to micromolar binding constants, and values below
Kd. Closer proximity to the pharmacophore target site
effects of the Thr114Phe mutation. Smaller ligands allow
9 Four ligands that formed an outlier group in terms of
orithms are indicated (box). (g) Examples of ligands with
harmacophore target is represented as a transparent cyan
are shown as optimised for each ligand. Ligand colours
eir binding. Non-carbon atoms are individually coloured
range). Left panel: the five ligands top-ranked by Glide SP
ximity of ligand to the pharmacophore target. Right panel:
Table 1. X-ray data collection and refinement statistics for
structures of Thr114Phe α1-antitrypsin and Gly117Phe α1-
antitrypsin
Thr114Phe
α1-antitrypsin
Gly117Phe
α1-antitrypsin
Data collection
Cell dimensions
a (Å) 113.8 58.8
b (Å) 39.6 149.3
c (Å) 90.3 77.3
β (°) 105.1 94.11
Molecules in asymmetric unit 1 3
Space group C2 P21
Resolution range (Å) 87.0–2.2 77.1–3.2
Rsym (%) 10.6 (49.3) 13.8 (58.8)
Completeness (%) 94.2 (90.2) 99.7 (99.7)
I/σI 15.3 (5.5) 11.5 (2.5)
Multiplicity 6.8 (6.8) 4.7 (4.8)
Structure refinement
No. of atoms (protein) 2847 8562
No. of atoms (water) 164 0
Rfree (%) 27.2 29.0
Rcryst (%) 22.4 24.2
Bave
Main chain 31.8 68.3
Side chain 34.7 74.6
Ramachandran plot statistics (%)
Favoured regions 89.8 74.6
Allowed regions 9.0 21.7
Generously allowed 1.2 2.8
Disallowed 0.0 0.9
r.m.s.d. from ideality
Bonds (Å) 0.007 0.010
Angles (°) 1.3 1.6
Values in parentheses refer to the highest-resolution shell.
Rsym=∑i(∑j|∑Iij− 〈Ii〉|)/∑i〈Ij〉, where j are the set of observations
for each reflection i.
Rcryst=∑i||Fo|−|Fc||/Fo|.
Rfree=Rcryst for 5% of reflections omitted from refinement.
Bave values are average temperature factors for all molecules in
the asymmetric unit.
860 Crystal Structures of Thr114Phe and Gly117Phe α1-Antitrypsinhighlighted by in silico screens that have identified
lead compounds that could fill the cavity and, hence,
reduce polymerisation.15 However, unlike the muta-
tions, all compounds that have proven effective in
vitro have also abolished inhibitory activity.
To understand the structural mechanisms by
which the effects of the Thr114Phe and Gly117Phe
mutations are conferred, we have crystallised both
α1-antitrypsin variants and solved their structures to
2.2 and 3.2 Å, resolution, respectively. The structure
of Thr114Phe α1-antitrypsin allows us to define a
novel target for pharmacophores to block polymer
formation whilst preserving inhibitory activity. The
structure of the Gly117Phe mutant shows that this
mutation exerts its effects by changes in both local
packing and the position of the F helix. We have
gone on to demonstrate that the two mutations
ameliorate the defect in folding of Z α1-antitrypsin
to the native, functional conformation in a COS-7
cell secretion model. These features extend our
understanding of the balance between fold stability
and metastability in α1-antitrypsin. The data are
consistent with both proposed β-sheet-A-linked
mechanisms of polymerisation. However, in the
case of the single-strand linkage model, they can be
integrated with previous findings to propose a
coordinated mechanism of β-sheet A expansion
from the native monomeric protein.
Results and Discussion
Effects of the Thr114Phe mutation arise from
partial cavity blockade
The 2.2 Å crystal structure of Thr114Phe α1-
antitrypsin adopts the classic structure of a serpin
fold in the native conformation (Fig. 1a and Table 1).
The polypeptide chain spanning residues 24–393 is
highly ordered with the exception of residues 344–
351. These comprise the P15–P8 section of the reactive
loop, a section that is disordered or associated with
high B-factors in other crystal structures ofmetastable
serpins.9,16,20–22 The key P1 methionine residue that
defines the inhibitory specificity of a serpin adopts a
canonical conformation.
Comparison of the structure of Thr114Phe α1-
antitrypsin with the 2.0-Å structure of wild-type α1-
antitrypsin that is also in the native conformation
[ProteinData Bank (PDB) code: 1QLP]16 shows a high
degree of overall similarity between the two proteins
(Fig. 1b). The root-mean-square deviation (r.m.s.d.) of
the mutant and wild-type structures, based on Cα
positions, is 0.4 Å. A number of critical regulators of
conformational change in α1-antitrypsin have pre-
viously been characterised. Apart from the cavity
flankingβ-sheetA, these are the proximal hinge of the
reactive loop,23 the arginine pocket stabilising the
loop at the P5 position,24 interstrand spacing in β-
sheet A,25 strand 1 of β-sheet C,26 the F helix9,12,27,28
and the shutter region29 (Fig. 1a). These are essentially
unchanged in the mutant structure compared to that
of wild-type α1-antitrypsin.The lack of perturbation elsewhere in the overall
structure of Thr114Phe α1-antitrypsin implies that
the mutation must be mediating its effect on the fold
stability of native α1-antitrypsin (Fig. 1c) from
within the cavity flanking β-sheet A. The cavity is
well defined in this high-resolution structure,
permitting interpretation of the effect of the muta-
tion on cavity filling at the side-chain level. The
precise location of the aromatic side chain of Phe114
was strongly indicated by the initial density seen
within the cavity adjacent to residue 114 when this
was modelled as an alanine (to minimise model
bias) prior to any restrained refinement (Fig. 1d).
Phe114 makes no interactions with nearby residues,
and therefore, its effects are entirely due to partial
filling of the cavity and changes in its packing
environment during unfolding and polymerisation.
The aromatic group of Phe114 closes the upper part
of the cavity (Fig. 1d) with its side chain just 3.7 Å
from Leu103 and 4.0 Å from Asn104 at the top of
helix D, distances that permit favourable van der
Waals contacts. These data support the importance
of β-sheet A compaction in stabilising the native
conformer against initial unfolding.
861Crystal Structures of Thr114Phe and Gly117Phe α1-AntitrypsinProof-of-principle in silico fragment screening
based upon the Thr114Phe mutation
The volume partially filling the cavity in
Thr114Phe α1-antitrypsin (Fig. 1e) is in a region of
high-solvent accessibility in the wild-type protein
and also yields the therapeutically desirable combi-
nation of effective blockade of polymerisation whilst
maintaining inhibitory function. Furthermore, it
does not alter the native α1-antitrypsin structure
beyond the cavity in any way. It is, therefore,
attractive to consider it a refined target or an ideal
pharmacophore volume, depicted in Fig. 1e as the
difference between surface representations of wild-
type and Thr114Phe α1-antitrypsin around residue
114. The estimated size of this ideal pharmacophore
is 59 Å3, equivalent to 22% of the total cavity volume
in wild-type α1-antitrypsin.
16 A similar reduction in
the size of lead compounds compared to those
identified by screening against the entire cavity
would improve the probability of success in rational
drug design.18 Lipinski's ‘Rule of 5’17 observes that
success in drug development is highly correlated
with the following: Mrb500 Da, lipophilic index
(logP)b5, ≤5 hydrogen-bond donors, ≤10 hydro-
gen-bond acceptors. A modified version of this, the
‘Rule of 3’, has been proposed to guide drug design
via exploration of a greater diversity of chemical
space using still smaller (b300 Da) molecular
fragments to identify potential ‘hits’.19 The mean
change in Mr in development from lead compound
to drug is +69 Da, and most effective drugs used in
clinical practice are 250–320 Da.19 Currently, the
lead compounds designed to block the entire cavity
and shown to be effective in vitro are at the upper
end of the desirable drug size (310–650 Da).15
To consider the region occupied by the
Thr114Phe mutation a meaningful pharmacophore
target, it must generate hits in silico that are
plausible in terms of mimicking the mutation's
partial cavity blockade, their predicted binding
affinities (Kd) and ‘drug-likeness’. The pharmaco-
phore target is centred between the middle of
strand 2 of β-sheet A (s2A) and the top of helix D
(Fig. 1f). It is close to polar residues (Asn104,
Thr114 and His139) and an area favourable for
hydrophobic contacts that may aid ligand coordi-
nation and binding, respectively. On the other
hand, unlike the entire cavity, this region is only
bounded by residues in one plane, which may be
challenging for some docking strategies. These
considerations make it hard to assume a priori
that plausible docking candidates would emerge
from in silico screening of fragment libraries.
We have therefore performed a proof-of-concept
screen of N70,000 fragments with Mr=150–250 Da
to assess the potential of the new pharmacophore
for identifying small compounds that can be
developed in rational drug design. The pharmaco-
phore centroid was set as the midpoint between
Thr114 (mutation site, middle of s2A) and Asn104
(top of helix D) for the purposes of our protocol.
Screens were performed to select hits on the basis ofdocking scores and ligand–target centroid proxi-
mity. By definition, all hits obey the Rule of 5 and
can only deviate from the Rule of 3 a single
hydrogen-bond acceptor. The best-scoring 0.1% of
ligands were taken forward for induced fit docking,
resulting in optimised docking of 65 unique ligands.
These had the following mean (±SD) characteristics:
Mr=207.2 Da (±21.7), estimated logP value=1.76
(± 0.81) and ligand–pharmacophore centroid
proximity=5.16 Å (±0.76). The fragments are
shown docked ensemble in relation to residues
104, 114 and 139 (Fig. 1f, left). The best docking
scores and proximity to the pharmacophore cen-
troid and sizes of all ligands docked by the induced
fitting protocol are also shown (Fig. 1f, right).
Docking scores calculated by Glide SP correlate
with predicted Kd values such that a value
b−6.8 kcal/mol correlates with a predicted micro-
molar Kd and a value b−8.2 kcal/mol correlates
with submicromolar affinity. Figure 1f illustrates
that this screen identified numerous fragment hits
achieving scores within this range. Examples of
docked ligands ranked highly by docking scores
and fragment–target centroid proximity are shown
in Fig. 1g.
Optimisation of this strategy is likely to require
screening 1–2 orders of magnitude more fragments
and ‘growing’ (up to Mr∼250 Da) of the best hits to
optimise specificity and drug-likeness ahead of in
vitro testing. However, the hits identified by this
preliminary screen are good candidates in terms of
size, predicted binding affinities and drug-likeness
for further development. Moreover, our screen also
identified compounds that docked well to sites
above the pharmacophore target site or interacted
with the front of β-sheet A (Fig. 1f). Similar hits will
aid the ‘growing’ of compounds for future in vitro
testing.
The Gly117Phe mutation alters aromatic ring
packing in the interface of β-sheet A with the
F-helix interface and induces a half-turn
downward shift in F-helix position
The structure of Gly117Phe α1-antitrypsin was
solved to 3.2 Å resolution (Table 1 and Fig. 2a),
allowing confident interpretation of the secondary
structure of the protein. The asymmetric unit
contained three molecules with minimal intermole-
cular contacts and in an arrangement not suggestive
of biologically significant multimerisation. No sig-
nificant changes are evident in β-sheet A, the shutter
region or strand 1 of β-sheet C in Gly117Phe α1-
antitrypsin relative to the wild-type protein. Elec-
tron density was not seen for residues 349–356 (copy
A), 348–356 (copy B) and 348–358 (copy C) of the
hypermobile reactive site loop.
Before incorporation of the Phe mutation into the
model or any restrained refinement had been
performed, clear density was apparent at the
mutation site, indicating that its side chain was
oriented away from β-sheet A towards the F helix
where significant changes were seen. To investigate
Fig. 2. The 3.2-Å structure of Gly117Phe α1-antitrypsin. (a) Crystal structure of Gly117Phe α1-antitrypsin (pink; β-
sheet A in dark blue). The helix F–β-sheet A linker region of the superposed native wild-type protein is shown (white).
Box: Initial observation of changes around the mutation site following molecular replacement and rigid-body fitting using
the wild-type α1-antitrypsin search model (1QLP, shown in yellow). At this stage, difference density (shown in red mesh,
contoured at 3 σ) for the mutation site and overlying F helix was calculated by excluding residues 117 and 160
(+surrounding 3.5 Å spheres) from a simulated annealing omit map to minimise model bias. Similar difference density
was seen in the F-helix region in all three copies of the molecule; the example of a single copy is shown. (b) Side-chain
packing of aromatic side chains in the helix F–β-sheet A interface in wild-type (left) and Gly117Phe (right) α1-antitrypsin.
Only β-sheet A (blue, stick representation) and helix F together with its linker region (gold, transparent cartoon and stick
representation) are shown. Residues involved in aromatic ring interactions are coloured red, and the mutation site at
Gly117 is indicated for wild-type α1-antitrypsin. (d) Increased biochemical stability of the native fold in the presence of the
Gly117Phe mutation. TUG-PAGE of wild-type (upper panel) and Gly117Phe (middle panel) α1-antitrypsin indicates that
the mutation confers increased stability of the native fold to increasing urea concentration. This is confirmed by CD
spectroscopy (lower panel). For Gly117Phe α1-antitrypsin (red curve, filled circles), unfolding begins at 2.0 M urea
(compared with 0.7M for the wild-type protein, black curve, open circles) and the transition midpoint occurs at 4.3 M urea
(compared with 3.4 M for wild-type α1-antitrypsin). Conditions are as described for Fig. 1c. Taken together, the urea
unfolding studies indicate increasing stability of the native fold in the order wild-typebThr114PhebGly117Phe
α1-antitrypsin.
862 Crystal Structures of Thr114Phe and Gly117Phe α1-Antitrypsinthese changes, we omitted the mutation site and the
overlying part of the F helix to generate a difference
density map of these areas with model bias
minimised. This was based upon the initial rigid-
body fit of the search model and did not use
noncrystallographic symmetry (NCS) restraints, yetit confirmed a half-turn shift of the F-helix along its
axis for all three molecules as well as side-chain
density for the underlying Phe117 residue (Fig. 2a,
boxed). In the refined structure, the F-helix is
displaced downwards (towards the bottom of s3A)
by half a turn relative to its position in the structure
863Crystal Structures of Thr114Phe and Gly117Phe α1-Antitrypsinof native wild-type α1-antitrypsin (2.7–3.5 Å
between equivalent Cα atoms). This compares with
an overall Cα r.m.s.d. of 1.2 Å for the rest of the two
structures. The F-helix shift is unlikely to be an
artefact of crystal packing as different copies of
Gly117Phe α1-antitrypsin have different packing
environments. Moreover, no F-helix changes are
required to permit packing of three molecules of the
native wild-type protein in orientations identical
with those of the three copies of Gly117Phe α1-
antitrypsin in the asymmetric unit (not shown).
Conversely, repacking of helix F–β-sheet A interface
residues, in particular Tyr160, is necessary to avoid
steric clashes with the adjacent Phe117 side chain
and sustain favourable hydrophobic interactions.
Figure 2b compares packing of the helix F–β-sheet A
interface in wild-type and Gly117Phe α1-antitrypsin.
In the refined structure of Gly117Phe α1-antitrypsin,
Phe117 forms the centre of a cluster of aromatic side
chains, interacting with Phe119, Phe143 and Tyr187
(all at distances of 3.5–5.5 Å). The side chain of
Tyr160 is in a solvent-exposed position in this
mutant in contrast to its buried position within the
helix F–β-sheet A interface in wild-type α1-anti-
trypsin but remains well placed for aromatic
interactions with two residues of this cluster,
Phe119 and Phe143. These differences therefore
account for the changed conformation of helix F in
Gly117Phe α1-antitrypsin compared to the wild-
type protein. They introduce an extra aromatic ring
into the helix F–β-sheet A interface in the mutant to
increase favourable packing interactions between
strands 1–3 of the β-sheet. These changes do not
obviously increase the degree of hydrophobic
interaction between the F helix (or its linker to
s3A, both shown in gold) and β-sheet A (blue).
However, it is striking that the biochemistry of this
mutant14 resembles that of α1-antitrypsin, carrying
what can now be regarded as a complementary
mutation, Tyr160Trp.28 Here, an extra aromatic ring
is introduced from the F-helix side into the helix
F–β-sheet A interface to project into a site adjacent to
Gly117. The Tyr160Trp mutation is associated with a
near-identical increase in thermal stability to that
seen with the Gly117Phe mutation. Both mutations
are also alike in achieving this without any reduc-
tion in inhibitory activity. The increased biochemical
stability conferred by the Gly117Phe mutation on
the native fold of α1-antitrypsin (Fig. 2c) is therefore
related to increased stabilisation of the F helix. The
relative contributions of the alterations in packing of
the helix F–β-sheet A interface and its half-turn
displacement towards the lower pole of the mole-
cule remain to be determined. Since these effects
involve alterations of the final folding of native α1-
antitrypsin and are mediated via interactions in a
hydrophobic interface, they may be hard to mimic
via rational drug design. However, the fact that the
position of the F helix is affected in the absence of
any other significant changes to the overall fold
supports the conclusion that this helix forms
relatively late in the folding process and indepen-
dent from the folding of other structural features.Effect of Thr114Phe and Gly117Phe mutations
on secretion of Z α1-antitrypsin from COS-7 cells
To relate our findings to drug design for α1-
antitrypsin deficiency, we attempted to character-
ise the stability and folding of the Thr114Phe/Z
and Gly117Phe/Z double mutants of α1-antitryp-
sin. These were produced as recombinant proteins
using the same overexpression system as the
crystallised proteins and purified by the same
method. The yield of both double mutants was
between 1 and 2 orders of magnitude lower than
that of wild-type and single-Phe mutant α1-
antitrypsin. The products were conformationally
heterogeneous with a mixture of native, latent [the
major product on non-denaturing and urea poly-
acrylamide gel electrophoresis (PAGE)] and poly-
meric conformers. The effects of the Thr114Phe
and Gly117Phe mutations on transient expression
and secretion of α1-antitrypsin containing the Z
mutation in a more physiological, eukaryotic cell
system were then assessed. Previous work has
shown that the Thr114Phe and Gly117Phe muta-
tions partially rescue the profound defect in the
overall secretion of α1-antitrypsin caused by the Z
mutation in a Xenopus oocyte system.14 These
effects are modest in proportion to the overall
deficit but are of considerable clinical interest since
disease severity correlates closely with rates of
polymerisation and (inversely) with circulating
levels of α1-antitrypsin.
30 However, this study
did not characterise the conformational state of
the secreted material. We therefore transformed
and transiently expressed M, Z, Thr114Phe/Z and
Gly117Phe/Z α1-antitrypsin in COS-7 cells. Ana-
lysis of cell lysates and culture media by Western
blot analysis of sodium dodecyl sulfate (SDS)-
PAGE showed increased secretion of α1-antitrypsin
in the double mutants compared with Z α1-
antitrypsin (Fig. 3a and b). These data were
consistent with those quantified by the more
sensitive pulse-chase system in Xenopus oocytes.
This increase in total α1-antitrypsin secretion was
related to a clear increase in secretion of native,
monomeric α1-antitrypsin as assessed by Western
blot analysis of non-denaturing PAGE (Fig. 3c,
arrow). The absolute concentrations of α1-antitryp-
sin in the culture media were very low relative to
those conventionally used to measure the inhibi-
tory activity of α1-antitrypsin. However, we were
able to detect inhibitory activity using an ELISA
technique in which bovine α-chymotrypsin was
used to capture functional α1-antitrypsin from
concentrated culture media. This indicated that
more functional material was secreted in the
presence of the double mutations (1.35 μg/ml for
Thr114Phe/Z and 0.35 μg/ml for Gly117Phe/Z α1-
antitrypsin) than with the Z mutation alone
(b0.16 μg/ml of active protein; below linear
range of detection by ELISA). These effects were
modest compared with the amount of functional
M α1-antitrypsin detected in the culture media
(N5 μg/ml; exceeding the maximum assessable in
Fig. 3. Characterisation of M, Z, Thr114Phe/Z and
Gly117Phe/Z α1-antitrypsin secreted from COS-7 cells.
Western blot analysis of α1-antitrypsin retained within or
secreted from COS-7 cells 2 days after transient transfec-
tion. (a) Western blot analysis of samples run on SDS-
PAGE with (b) luciferase transfection control for cell lysate
samples [same gel as (a)]. (c) Western blot analysis of
samples run on non-denaturing PAGE. Lanes 1–5, cell
lysates; lanes 6–10, culture media. Lane 1, empty vector
control—cell lysate; lane 2, M α1-antitrypsin—cell lysate;
lane 3, Z α1-antitrypsin—cell lysate; lane 4, Thr114Phe/Z
α1-antitrypsin—cell lysate; lane 5, Gly117Phe/Z α1-anti-
trypsin—cell lysate; lane 6, empty vector control—super-
natant; lane 7, M α1-antitrypsin—supernatant; lane 8, Z
α1-antitrypsin—supernatant; lane 9, Thr114Phe/Z α1-
antitrypsin—supernatant; lane 10, Gly117Phe/Z α1-anti-
trypsin—supernatant. Arrow indicates migration of
native α1-antitrypsin secreted into the culture media on
non-denaturing PAGE.
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with the appearances of native protein by non-
denaturing PAGE (Fig. 3c).
The increased secretion of native α1-antitrypsin
from cells expressing the double mutants com-
pared to those expressing Z α1-antitrypsin was
also associated with an increase in the amount of
polymeric material seen in the media. We cannot
formally exclude the possibility that these poly-
mers were formed intracellularly and then secreted
differentially. However, the lack of any observable
difference in total and polymeric intracellular α1-
antitrypsin levels between the different constructs
does not support this hypothesis. We therefore
favour the alternative explanation that the extra-
cellular polymers are formed from α1-antitrypsin
that is secreted in the native conformation. Taken
together, these data support the conclusion that the
Thr114Phe and Gly117Phe mutations have modest
but detectable effects on increasing secretion of
functional native α1-antitrypsin on the background
of the severe Z mutation in eukaryotic cells.
However, these double mutants remain prone to
conformational change and polymerisation.Relating the crystal structures of Thr114Phe and
Gly117Phe α1-antitrypsin to the single- and
double-strand linkage models of polymerisation
The Thr114Phe and Gly117Phe mutations act by
differentmechanisms to increase the global stability of
native α1-antitrypsin. Expansion of β-sheet A is a
common feature in both proposed mechanisms of
polymerisation.9,13 In order forα1-antitrypsin to adopt
either M⁎ conformation, residue 114 must move
laterally by 4.6 Å in the plane of β-sheet A. This is
limited by local steric clashes in Thr114Phe α1-
antitrypsin. In the case of the Gly117Phe mutation,
the structural mechanism whereby the changes in the
vicinity of the F helix may impede formation of a β-
hairpin donor/acceptor M⁎ species is less intuitive.
There is no apparent increase in stabilising interactions
between the helix F–s3A linker and s5A, and the
changes in packing in the interface between the F helix
and β-sheet Awould not of themselves be expected to
impede opening of the β-sheet. Nevertheless, our data
are not inconsistent with this model since they may
simply reflect overall cooperativity of the final steps on
the folding pathway (and initial steps on the unfolding
pathway) for α1-antitrypsin. However, our findings
can bemechanistically integratedwith other biochem-
ical data for the native-to-M⁎ transition posited for the
single-strand linkage model in which opening of the
s4A site is associated with partial intramolecular loop
insertion. Various data support the following features
of this model: upper s4A opening precedes lower s4A
opening9,25,31,32 and is associatedwith partial insertion
of the reactive site loop.9,33,34 Subsequent lower s4A
opening around the site of P8 residue insertion is
associated with breaking of a network of interactions
between s4A, s5A and shutter region residues.25 This
can be induced by the insertion of a cleaved reactive
loop or a peptide analogue into β-sheet A from the
P14–P9 sites, producing species that are highly
polymerogenic.31,32,35,36 In α1-antitrypsin, modelling
the insertion of the reactive site loop to the P12position
necessitates both the release of s1C and remodelling of
the upper helix F—secondary structural changes
known to occur during the formation of polymers
from native α1-antitrypsin.
12,26 However, stabilisation
of the upper turns of the F helix and/or its downward
displacement as seen in the structure of Gly117Phe α1-
antitrypsin will reduce the propensity for its remodel-
ling. It will, therefore, reduce M⁎ formation if such
remodelling is integral to the formation of the
intermediate. This process is shown as a schema in
Fig. 4. The model of the single-strand donor/acceptor
M⁎ is shown following energy minimisation and
simulated annealingmolecular dynamics (coordinates
are supplied as Supplementary Data).Conclusion
The data presented here demonstrate in crystal-
lographic detail two mechanisms that greatly stabilise
the native fold in α1-antitrypsin without abolishing its
inhibitory function. These mechanisms are likely to
Fig. 4. Schema for formation of a partially loop-inserted M⁎ species from native α1-antitrypsin. Findings from the
Thr114Phe and Gly117Phe α1-antitrypsin crystal structures are incorporated together with previous observations of
requirements for loss of the s1C26 strand, remodeling of the F helix9,12,28 and destabilising of interactions involving shutter
region residues.25 Sequential insertion of the reactive loop into the upper s4A position is depicted by two chimeras. These
are derived from structures of native (1QLP) and latent (1IZ2) α1-antitrypsin, murine α1-antichymotrypsin (1YXA—
demonstrating changes associated with opening of the P14 acceptor site) and thyroxine binding globulin (2CEO—
demonstrating changes on expansion at the P12 insertion site). In all cases, the reactive loop modelled is that of α1-
antitrypsin. The final image shows the α1-antitrypsin M⁎ model, generated as described in Materials and Methods, after
energy minimisation with simulated annealing molecular dynamics. The effects of mutations that will facilitate this
transition are shown in red whilst those that block it are shown in blue. Thus, in this scheme, Thr114Phe retards M⁎
formation by cushioning β-sheet A against expansion whilst Gly117Phe stabilises the upper turns of helix F and abolishes
the steric requirement for their remodelling in response to partial loop insertion. Conversely, mutations may accelerate
polymerisation by favouring partial loop insertion (e.g., Z) or by opening the lower s4A position directly (e.g., Siiyama).
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antitrypsin when the Thr114Phe or Gly117Phe muta-
tions occur in the context of the Z mutation in
eukaryotic cells although the double mutants remain
highly polymerogenic. The high-resolution structural
characterisation of the Thr114Phe mutation presents a
more precise pharmacophore target for screening of
small fragments capable of mimicking its effects.
These data are generally consistent with either the
single-strand or β-hairpin linkage models of poly-
merisation. However, they suggest a specific mechan-
ism of propagated conformational change in the case
of the single-strand model and, therefore, open up
new approaches for further studies to test its
applicability in this important pathological pathway.
Materials and Methods
Site-directed mutagenesis, protein expression,
purification and characterisation
QuikChange mutagenesis (Stratagene, California, USA)
was used to introduce the Thr114Phe, Gly117Phe and/or
Z (Glu342Lys) mutations into His-tagged α1-antitrypsin inthe pQE31 vector37 to create single- or double-mutant
constructs. The full-length sequences of the mutated α1-
antitrypsin genes were confirmed, and plasmids were
transformed into XL-1 Blue Escherichia coli cells. The wild-
type and mutant proteins were expressed and purified as
described previously.14 The final products were stored in
10 mM Tris/HCl, pH 7.4, 10 mM NaCl and 1 mM
ethylenediaminetetraacetic acid. Product purities were
confirmed by non-denaturing PAGE, SDS-PAGE and
transverse urea gradient (TUG)-PAGE. Further character-
isation of urea stability by circular dichroism (CD) was
performed as described previously.
The Z, Thr114Phe/Z and Gly117Phe/Z α1-antitrypsin
constructs for transient transfection of COS-7 cells were
prepared by a combination of cloning, subcloning and
site-directed mutagenesis in the pcDNA3.1 vector. All
constructs were confirmed by sequencing of the whole
gene. COS-7 cells were transfected and cultured as
described previously.38 Samples of the cells in culture
media were collected 2 days after transfection. Cells and
culture media were separated by centrifugation at 500g
for 10 min. Cell lysates and culture media were prepared
and assessed by SDS-PAGE and non-denaturing PAGE
followed by Western blot analysis for α1-antitrypsin as
described previously.38,39 Inhibitory activity was assessed
with an α-chymotrypsin-based ELISA. Each well of a 96-
well plate was coated overnight with 100 μl of 5 mg/ml
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before incubating for 15 min at 37 °C with 100 μl of
culture medium concentrated 7.5 times (this did not affect
relative proportions of polymeric to total α1-antitrypsin).
After further washing to remove unbound material, the
amount of functional material captured was assessed by
incubation with 100 μl of purified polyclonal antibody
against α1-antitrypsin used at 1 μg/ml for 2 h at 4 °C in the
presence of 0.25% (w/v) bovine serum albumin as a
blocking agent, followed by washing and incubation with
100 μl of horseradish-peroxidase-conjugated anti-rabbit
secondary antibody (Sigma-Aldrich, Dorset, UK). The
plate was washed and the enzymatic activity was
developed with 3,3′,5,5′-tetramethylbenzidine substrate
(Sigma-Aldrich). The colour was allowed to develop for
approximately 10 min and was halted by the addition of
100 μl of 1 M sulfuric acid to each well. The absorbance
was read at 450 nm.
Crystallisation, data collection and structure solution
Both Thr114Phe and Gly117Phe α1-antitrypsin were
crystallised by the hanging drop vapour diffusion method
in 4-μl drops containing equivalent volumes of 10 mg/ml
protein andmother liquor at 20 °C. Thr114Pheα1-antitrypsin
was crystallised using 0.1 M Li2SO4, 0.1 M Tris/HCl pH 8.5,
and 31% polyethylene glycol (PEG) 4000 (w/v). Gly117Phe
α1-antitrypsin was crystallised using 0.1 M Li2SO4, 0.1 M
Tris/HCl, pH 8.5, and 25% PEG 4000 (w/v). Crystals were
cryoprotected by the addition of 16% PEG 400 (w/v) (for
Thr114Phe α1-antitrypsin) or 16% ethylene glycol (w/v) (for
Gly117Phe α1-antitrypsin) before being flash cooled in liquid
nitrogen. Diffraction data for Thr114Phe α1-antitrypsin were
collected at station I03 at the Diamond synchrotron
(Oxfordshire, UK), and those for Gly117Phe α1-antitrypsin
were collected at station ID14.4 at the European Synchrotron
Radiation Facility (Grenoble, France). Data were processed
using MOSFLM40 and scaled using Scala.41 Molecular
replacement was carried out using MOLREP42 with protein
coordinates from the 2.0-Å structure of wild-type α1-
antitrypsin (1QLP)16 as the search model. Refinements for
both structures were carried out using Refmac43 and CNS.44
Whilst the asymmetric unit of Thr114Phe α1-antitrypsin
contained only a single molecule, that of the Gly117Phe
mutant contained three molecules. Two molecules were
related by a 2-fold rotational symmetry axis, the third was
related to the others by translation without an n-fold
rotational axis. NCS was therefore applied during the
solution of the structure of Gly117Phe α1-antitrypsin. This
was initially applied with all three molecules constrained to
be identical. Once Rfree values had converged between
successive refinement rounds, the NCS was subsequently
applied with weighted restraints. In three regions where the
electron density indicated increased intermolecular varia-
bility [residues 90–112 (helix D and linker to s2A), 150–180
(helix F and linker to s3A) and 343–363 (reactive site loop)],
NCS restraints were not applied. Manual rebuilding of
modelswas performed inCoot,45 and figureswereproduced
using PyMOL46 and Chimera.47
Characterising the pharmacophore target implied by
the Thr114Phe mutation
The cavity flanking β-sheet A in α1-antitrypsin was
defined and quantified using SURFNET.48 As described
previously,16 grid separations of 0.8 Å and probe spheres
of 2.0–4.0 Å radii were used. The extra volume occupied
within the cavity by the Thr114Phe mutation wascalculated by subtracting the volume of the cavity in the
mutant from that in the wild-type protein. Similarly, an
ideal pharmacophore capable of mimicking the partial
cavity blockade caused by the mutation was illustrated by
subtraction of the surface map of residue 114 in wild-type
α1-antitrypsin from that of Thr114Phe α1-antitrypsin using
SURFNET.48
In silico screens of compound libraries
The fragment-like subset of the ZINC database49
(−2≤xLogP≤3, Mr=150–250 Da, ≤3 rotational bonds,
≤2 hydrogen-bond donors and ≤4 hydrogen-bond
acceptors) was selected for initial prescreening to identify
drug- and lead-like compounds capable of significant
modification to optimise specificity without unfavourably
increasing size. The subset labelled ‘usual’, containing all
fragment-like molecules protonated in the pH range 5.75
to 8.25, was downloaded. Programs from the Schrödinger
Suite 2007 (Schrödinger LLP, New York, NY, USA) were
used for in silico docking. Fragments were preprocessed
using LigPrep version 2.1. The original ionisation state
was retained and ‘desalt’ and ‘tautomer generation’ flag
settings were used. Chiralities were determined from the
original ZINC database structures, and one low-energy
ring conformation was allowed. This procedure resulted
in a total of 70,925 small-molecule structures for docking.
The protein was prepared using Maestro version 8.0
(Protein Preparation Wizard). Hydrogens were added,
and all waters were deleted from the structure of wild-
type α1-antitrypsin. Hydrogen bonds were optimised, and
the structure was minimised within 0.30 Å r.m.s.d. from
the initial structure. The potential energy grid was pre-
calculated using a box centred on the centroid of residues
Asn104 and Thr114 to prepare the binding site for
docking. The box was 39 Å in each dimension, but the
ligand centre was constrained to lie within 14 Å of the box
centre. No additional constraints were used.
Initial screening of the 70,925 ligands was performed
using Glide version 4.5, to generate a range of putative
ligand–receptor interactions (poses). The best pose for each
ligand was calculated using Emodel and retained. Ranking
between ligands was then performed using the Glide SP
score. All Glide parameters were left to their default values.
The top 70 (b0.1%) ligands resulting from this Glide SP run
were then submitted to the Induced Fit Docking protocol, a
three-step docking process. Preliminary docking by Glide
SPused a scaling factor for vanderWaals radii of 0.5 for both
the ligand and the receptor. For each ligand, the best 20
poseswere retained. Prime version 1.6 was used to optimise
receptor side chains within 5.0 Å of each posed ligand.
Finally, ligands were redocked into the optimised struc-
tures. The resulting poses were ranked using a composite of
the Glide SP (binding site energy) and the Prime (molecular
mechanics+solvation energy function for the protein–
ligand complex) scores as previously described.50
The molecular weight and other descriptors for the set
of docked ligands were calculated using the MOE suite
(MOE 2006.08, Chemical Computing Group, Montreal,
QC, Canada). Prior to descriptor calculation, the partial
charges on all atoms were recalculated using the default
MOE force field (MMFF94x), and adjustment of hydro-
gens and lone pairs was allowed.
Modelling α1-antitrypsin in the M⁎ conformation
To model wild-type and mutant α1-antitrypsin in the
partially loop-inserted M⁎ conformation, we used the 2.2-
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51 as the
initial template. In the latent conformation, the reactive
loop is fully inserted into β-sheet A as its fourth strand
(s4A). This structure was chosen as it is the highest-
resolution structure of α1-antitrypsin with an expanded β-
sheet A. Mutations were restored back to the wild-type
sequence. The residues of the reactive site loop were
threaded into the conformation adopted in the structure of
δ Leu55Pro α1-antichymotrypsin (1QMN)
9 using SWISS-
MODEL.52 As the reactive loop of α1-antitrypsin is four
residues shorter than that of α1-antichymotrypsin, this
required stripping out of s1C to connect it directly with
s4B. The model was regularised in Coot before under-
going energy minimisation, simulated annealing and final
energy minimisation using SANDER, with the protein
parameterised using the AMBER99SB force field.53 The
upper turn of helix F required greater freedom during
simulated annealing than the rest of the molecule to allow
successful energy minimisation. This was achieved by
conservative relaxation of restraints on this region relative
to the rest of the molecule.
Accession numbers
Coordinates and structure factors are deposited in the
PDB with accession number 3DRM for the structure of
Thr114Phe α1-antitrypsin and 3DRU for the structure of
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